Gilead Sciences Company Description
Gilead Sciences has biotech balms for infectious diseases, including hepatitis, HIV, and infections related to AIDS. The company's HIV franchise includes blockbuster Truvada, a combination of two of its other drugs, Viread and Emtriva. It co-promotes another HIV treatment, called Atripla, in the US and Europe with Bristol-Myers Squibb. Other products on the market include AmBisome, used to treat systemic fungal infections such as those that accompany AIDS; Vistide, for AIDS-related eye infections; and hepatitis B antiviral Hepsera. Outside of the infectious disease realm, Gilead has won FDA approval for Letairis, a treatment for pulmonary arterial hypertension (PAH).
View the Comprehensive Company Description for Gilead Sciences
The Company Description provides a historical perspective of Gilead Sciences's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Gilead Sciences's evolution in the marketplace.
